Haley Naik, M.D., Discusses Hidradenitis Suppurativa at Annual AAD Meeting
Haley Naik, M.D., associate professor of dermatology at the University of California, San Francisco, School of Medicine, led a discussion about hidradenitis suppurativa today at the annual American Academy of Dermatology meeting in New Orleans.
Haley Naik, M.D., associate professor of dermatology at the University of California, San Francisco, School of Medicine, led a discussion about hidradenitis suppurativa today at the annual American Academy of Dermatology meeting in New Orleans.
Naik says the growing prevalence of the disease is likely the result of increased diagnosis and public awareness and not a population increase in the condition.
Although studies have shown an association between hidradenitis suppurativa and metabolic disorders, Naik said the evidence does not point toward a causal relationship and that weight loss.
Humira (adalimumab) is approved as a treatment for hidradentis suppurativa. Naik, who said it may be time for clinicians to consider using biologics earlier in the course of hidradenitis suppurativa, said the launching of biosimilars to Humira this year may improves access to treatment for the condition.
Opzelura May Reduce Need for Other Treatments in Atopic Dermatitis | AAD 2025
March 11th 2025Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics during the 12 months after treatment with the topical nonsteroidal, according to study findings presented at the 2025 American Academy of Dermatology annual meeting.
Read More
Makeup and Skin Care Products Contain 'Forever Chemicals' | AAD 2025
March 10th 2025More than 200 products from 28 makeup, sunscreen, and shaving cream brands contained Teflon and other forever chemicals, according to a new study presented at the American Academy of Dermatology annual meeting.
Read More
Study Finds Opzelura Used As-Needed Improves Quality of Life | AAD 2025
March 10th 2025The reduction in itch was the greatest contributor to quality-of-life improvement for adolescents and adults with atopic dermatitis, according to a new study presented at the American Academy of Dermatology annual meeting.
Read More
